



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics Committee

April 26th, 2017

Location: Diamond, Rooms B10 and B11
Time: 2:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Committee Members Present:

Bradley Henry, M.D., Chair
Tom Kines, R.Ph., Vice Chair
Jeffrey V. Ashley, M.D.
Adam Breinig, D.O.
Scott Brown, R.Ph.
Chris Terpening, Pharm.D., PhD.
Heather Jones, PA-C
Mary Payne, M.D.
Toni DiChiacchio, DNP, APRN
Karrie Juengel, Pharm.D.
Hazi Nazha, M.D.
Steve Neal, Pharm.D.

Division of Medicaid Staff Present:

Vicki Cunningham, R.Ph.
Brian Thompson, Pharm.D., MS
Doug Sorvig

Contract Staff/GHS Staff Present:

Brent Breeding, R.Ph.
Jacquelyn Hedlund, M.D.
Jennifer Seymour, Project Coordinator

Other Contract / State Staff Present:

By Phone:
Kenneth Hilsbos, M.D.

Absent:

I. Call to Order

Dr. Bradley Henry, Chairman, called the meeting to order at 2:07pm

II. Welcome and Introductions

P&T committee members introduced themselves, including two new members; Toni DiChiacchio and Karrie Juengel.

III. Administrative Items / Updates

Vicki Cunningham provided ground rules for public comment.

A. Approval of the October 26th, 2016 Minutes

Dr. Neal made a motion to approve the minutes from the October 26th meeting and Dr. Terpening seconded the motion. A vote was taken, all were in favor and the minutes were approved.

B. PDL Compliance/Generic Percent Report Updates

Dr. Hedlund walked the committee through the Generic Percent and PDL Compliance reports provided to the Committee. PDL compliance for Q1 2017 was high overall at 83.23%. In some categories with less generic use, PDL compliance was high due to utilization of preferred brands. Overall generic utilization for Q1 2017 was at 87.5%

IV. Public Comments

No speakers signed in for comments.

V. Executive Session

Dr. Henry made a motion to move to executive session.

The Committee adjourned for executive session at 2:10pm

The Committee reconvened at 2:52pm

VI. New Business

A. New Drug Reviews

i. SUSTOL (granisetron)

ANTIEMETICS	
5HT3 RECEPTOR BLOCKERS	
ondansetron ODT, solution, tablets	ANZEMET (dolasetron) granisetron

	GRANISOL (granisetron) ondansetron vials SANCUSO (granisetron) SUSTOL (granisetron) ZOFRAN (ondansetron) ZUPLLENZ (ondansetron)	
--	-------------------------------------------------------------------------------------------------------------------------------------------------------	--

Dr. Neal made a motion to approve the change to the Antiemetics category as recommended; seconded by Dr. Chris Terpening. All members were in favor and the motion was approved.

ii. ZURAMPIC (lesinurad)

ANTIHYPERURICEMICS		
URICOSURIC		
probenecid	ZURAMPIC (lesinurad)	* Full PA criteria may be found on the PA Criteria page by clicking the hyperlink.

Dr. Terpening made a motion to approve the change to Antihyperuricemics category as recommended; seconded by Dr. Neal. All members were in favor and the motion was approved.

i. ONZETRA XSAIL (sumatriptan)

ANTIMIGRAINE AGENTS, TRIPTANS ^{AP}		
TRIPTANS		
naratriptan rizatriptan rizatriptan ODT sumatriptan nasal spray/injection sumatriptan tablets	almotriptan AMERGE (naratriptan) AXERT (almotriptan) FROVA (frovatriptan) frovatriptan IMITREX INJECTION (sumatriptan) ^{CL} IMITREX NASAL SPRAY (sumatriptan) IMITREX tablets (sumatriptan) MAXALT (rizatriptan) MAXALT MLT (rizatriptan) ONZETRA XSAIL (sumatriptan) RELPAX (eletriptan) SUMAVEL (sumatriptan) ZECUITY PATCH (sumatriptan) ZEMBRACE SYMTOUCH (sumatriptan) zolmitriptan zolmitriptan ODT ZOMIG (zolmitriptan) ZOMIG ZMT (zolmitriptan)	<p>In addition to the Category Criteria: Three (3) day trials of each preferred agent will be required before Imitrex injection is authorized.</p> <p>* In addition to the class criteria, Onzetra Xsail requires a trial of both the nasal and injectable forms of sumatriptan.</p>

Dr. Adam Breining made a motion to approve the change to the Antimigraine Agents, Triptans category as recommended; seconded by Dr. Chris Terpening. All members were in favor and the motion was approved.

ii. **INVOKAMET XR (canagliflozin/metformin)**

HYPOGLYCEMICS, SGLT2 INHIBITORS	
SGLT2 COMBINATIONS	
	GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canagliflozin/metformin) INVOKAMET XR (canagliflozin/metformin) SYNJARDY (empagliflozin/metformin) XIGDUO XR (dapagliflozin/metformin)

Dr. Hani Nazha made a motion to approve the change to the Hypoglycemics, SGLT2 Inhibitors category as recommended; seconded by Dr. Adam Breining. All members were in favor and the motion was approved.

iii. **RELISTOR TABLET(methylnaltrexone)**

IBS/SHORT BOWEL SYNDROME/SELECTED GI AGENTS		
TRIPTANS		
AMITIZA (lubiprostone) ^{CL*} LINZESS (linaclotide) ^{CL*}	alosetron** FULYZAQ (crofelemer)* LOTRONEX (alosetron)** MOVANTIK (naloxegol)* RELISTOR INJECTION (methylnaltrexone)* RELISTOR TABLET (methylnaltrexone)* VIBERZI (eluxadoline)**	* Full PA criteria may be found on the PA Criteria page by clicking the hyperlink. **For the indication of IBS-diarrhea, alosetron (Lotronex) and Viberzi have specific PA criteria which may be found on the PA Criteria page by clicking the hyperlink.

Dr. Adam Breining made a motion to approve the changes to the Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents category as recommended; seconded by Dr. Chris Terpening. All members were in favor and the motion was approved.

iv. **BROMSITE (bromfenac)**

OPHTHALMICS, ANTI-INFLAMMATORIES^{AP}	
dexamethasone diclofenac DUREZOL (difluprednate) fluorometholone flurbiprofen ketorolac prednisolone acetate prednisolone sodium phosphate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) BROMDAY (bromfenac) bromfenac BROMSITE (bromfenac) FLAREX (fluorometholone) FML (fluorometholone)

	FML FORTE (fluorometholone) FML S.O.P. (fluorometholone) ILEVRO (nepafenac) LOTEMAX DROPS, OINTMENT (loteprednol) LOTEMAX GEL (loteprednol) MAXIDEX (dexamethasone) NEVANAC (nepafenac) OMNIPRED (prednisolone) OZURDEX (dexamethasone) PRED FORTE (prednisolone) PRED MILD (prednisolone) PROLENSA (bromfenac) RETISERT (fluocinolone) TRISENCE (triamcinolone) VEXOL (rimexolone) XIBROM (bromfenac)	
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Dr. Adam Breinig made a motion to approve the changes to the Ophthalmics, Anti-Inflammatories category as recommended; seconded by Dr. Chris Terpening. All members were in favor and the motion was approved.

VII. Old Business

No old business was identified for discussion.

VIII. Next Meeting – Wednesday, August 23, 2017,

2 PM - 5 PM, Diamond Building, Rooms B10 and B11

IX. Other Business

No other business was identified for discussion.

X. Adjournment

Dr. Bradley Henry adjourned the meeting at 3:01pm